A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

NCT06422403 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular
Gastric Adenocarcinoma
GastroEsophageal Cancer
Oesophageal Cancer
Non-small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Extended Dosing Interval - A
DRUG: Extended Dosing Interval - B
DRUG: Extended Dosing Interval - C
DRUG: Standard of Care - A
DRUG: Standard of Care - B
DRUG: Standard of Care - C

Sponsor

National University Hospital, Singapore